Accelerating a New Era of Genetic Medicine for Neuromuscular Disease
About Us
Enabling next-generation genetic medicine.
Kinea Bio was founded in 2020 by highly-respected scientific leaders in the neuromuscular disease space with a history of bench-to-bedside innovations.
Our Latest News
-
![]()
Chief Operating Officer Seung Wook Oh, PhD authors review article on non-viral gene therapy delivery for Duchenne Muscular Dystrophy
September 2, 2024
-
![]()
A Breakthrough Gene Therapy Strategy for Kinea's Lead Program, DMD, Published in Nature
July 17, 2024
-
![]()
Kinea Awarded Pilot Grant by University of Washington’s Center for Translational Muscle Research
June 17, 2024
-
![]()
Kinea Selected for Fast-Track NIH Small Business Innovation Research Funding
April 19, 2024
-
![]()
Kinea Bio Presents at Life Science Innovation Northwest Annual Conference
April 17, 2024
-
![]()
Jeffrey Chamberlain, Co-founder, Interviewed on MDA Quest Podcast
April 1, 2024
-
![]()
Parent Project Muscular Dystrophy Funds Kinea Bio
February 13, 2024
-
![]()
Jeffrey Chamberlain, Co-founder, Receives Muscular Dystrophy Association Legacy Award
January 30, 2024
-
![]()
Jeffrey Chamberlain, Co-founder, Elected President of American Society for Gene and Cell Therapy
May 20, 2023
-
![]()
Hichem Tasfaout, Contributing Scientist, Delivers Prestigious ASGCT Presidential Address at Annual ASGCT Meeting
May 18, 2023
-
![]()
The Speak Foundation Funds Kinea Bio
June 2, 2022
-
![]()
CureLGMD2i Funds Kinea Bio
May 10, 2022
